Monte Rosa Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Plans
During the fiscal quarter ended December 31, 2025, none of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act)adopted, terminated ormodified a Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading agreement (as defined in Item 408(c) of Regulation S-K), except as described in the table below:
| Name and Title | Action | Action Date | Duration of Trading Arrangements | Rule 10b5-1 Trading Arrangement? (Y/N)* | Aggregate Number of Securities Subject to Trading Arrangement |
|---|---|---|---|---|---|
| Markus WarmuthChief Executive Officer | Adopt | May 14, 2025 | August 13, 2025 - August 13, 2026 | Y | Up to 32,000 shares of common stock to be sold (in four tranches of up to 8,000 shares each subject to vesting of RSUs) |
- Denotes whether the trading plan is intended, when adopted, to satisfy the affirmative defense of Rule 10b5-1(c).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.